Highlights Guardant Health, Inc.

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 06/03/2026 GMT			5-day change	1st Jan Change
91.20 ^USD	-1.49%		-2.88%	-10.71%

03-05	Guardant Health Insider Sold Shares Worth $3,812,661, According to a Recent SEC Filing	MT
03-04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI

Highlights

03-04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI
02-19	(GH) Guardant Health Expects Full Year 2026 Revenue Range $1.25B - $1.28B, vs. FactSet Est of $1.25B	MT
02-19	Guardant Health Q4 Adjusted Loss Narrows, Revenue Rises; 2026 Revenue Guidance Set	MT
02-19	Earnings Flash (GH) Guardant Health, Inc. Reports Q4 Revenue $281.3M, vs. FactSet Est of $272.4M	MT
02-19	Earnings Flash (GH) Guardant Health, Inc. Posts Q4 Adjusted Loss $0.50 per Share, vs. FactSet Est of $-0.77	MT
02-19	Guardant Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-19	Guardant Health, Inc. Provides Revenue Guidance for the Fiscal Year 2026	CI
02-18	Guardant Health, Inc. (NasdaqGS:GH) acquired Metasight Diagnostics for approximately $150 million.	CI
02-02	Guardant Health, Inc. Announces Publication of the Largest Study to Date Evaluating Circulating Tumors forMRD Detection in Patients with Rescted Stage III Colon Cancer After Surgery and Before Adjuvant Chemotherapy	CI
01-22	Guardant Health, Inc. Receives FDA Approval for Guardant360®? CDx as Companion Diagnostic for BRAFTOVI®? (Encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer	CI
01-19	Guardant Health, Inc. Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform	CI
01-12	Independence, Under Review
01-12	Guardant Health Sees 39% Rise in Q4 Preliminary Revenue	MT
01-11	Guardant Health Q4 total revenue of approx $280 million	RE
01-11	Guardant Health, Inc. Provides Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-08	Guardant Health, Inc.'S Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families	CI
12-11	Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S	CI
12-09	Guardant Health, Inc. and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy	CI
12-05	Certain Common Stock of Guardant Health, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.	CI
11-12	Guardant Health, Inc. Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access	CI
11-10	Guardant Health, Inc. Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring	CI
11-06	New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response	CI
11-05	Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Jobs Data	MT
30/10/25	Top Midday Gainers	MT
30/10/25	Guardant Health Shares Jump Following Better-Than-Expected Q3 Results, Higher 2025 Revenue Outlook	MT